-
New research highlights the extent of the new coronavirus transmission by aerosol. Droplets smaller than 100 μm containing viral particles can remain suspended in the air for a long time and be inhaled.
-
A review on the effectiveness of general screening for SARS-CoV-2, compared to absence of screening and accuracy of general screening in people apparently not affected by COVID-19 were published.
-
The media in German-speaking Switzerland have enthusiastically reported on a study suggesting that Echinaforce® could be effective against SARS-CoV-2, raising doubts in the scientific community.
-
Dr. Paul Garassus, president of the UEHP, discusses the role of the private health system in the current COVID-19 pandemic and the regional space for improvement in this contingency.
-
The risk of falling during stroke rehabilitation is an important issue but with little available data. A recent study shows unexpected results on mobilization in the sub-acute phase after strokes.
-
Myositides can occur idiopathically or - much less well known - in combination with medication. If left untreated, severe, irreversible or even fatal progressions are possible.
-
Before Sir Alexander Fleming discovered penicillin in 1928, syphilis treatments were nightmarish and included mercury vapors or getting injected with a potentially fatal disease.
-
Studies show a causal relationship between different risk factors and microangiopathies, one of the main causes of vascular dementia. They also shed light on the effectiveness of therapeutic approaches.
-
A study saw a 13% rate of serious neurological complications in hospitalized COVID-19 patients. Mortality rate was almost 40% higher than in hospitalized COVID-19 patients without neurological complications.
-
October 29 is World Stroke Day and stroke therapy is a core topic at the 93rd DGN Congress. Reducing stroke mortality will depend on treating more patients, faster, specially within the 'golden hour' after stroke.
-
Most brain changes after a COVID-19 infection are not caused by the virus, but by the body's immune response. The findings are from a study that examined 43 deceased people infected with SARS CoV-2.
-
Only riluzole can slow down ALS progression, and multimodal supportive therapy is the option left. A phase-II trial showed that oral administration of sodium phenylbutyrate and taurursodiol could delay progression.
-
A major meta-analysis confirms the advantages of catheter intervention for more severe and moderate strokes. This therapeutic option must also be made available in rural regions.
-
The device will be called VIKI (VIrus KIller) and can be used in schools, public offices, hospitals, dental surgeries and businesses. It aims to remove over 99.9% of bioaerosol particles.
-
An algorithm detects signs of osteoarthritis on an MRI scan before the first symptoms appear. With artificial intelligence, treatments could rely on drugs rather than surgery.
-
The latest findings in dermatological pathology - from newly discovered diseases to the background of "COVID toes" are briefly and concisely summarised.
-
OLLs are often triggered by medication or are a concomitant symptom of underlying inflammatory diseases, and are very similar to oral lichen planus. Differentiation and finding triggering factors is challenging.
-
Based on the immune cells involved in the inflammatory reaction, phenotypic differences occur. For optimal therapy, factors must be taken into account to treat the diseases’ subgroups
-
Chronic hand eczema (CHE) is a recurrent inflammatory reaction around the hands. Often visible, it adds a psychological burden for those affected. Delgocitinib showed a good effect with a favorable side effect profile.
-
Biologics have significantly improved the treatment of dermatological diseases. Their use in the treatment of melanoma and atopic dermatitis was discussed during the virtual EADV Congress on 31 October 2020.
